Strategic fit High potential for partnerships with oncology players seeking gamma-delta T cell engagement platforms, especially in solid and hematologic malignancies where LAVA's gamma-delta bsTCEs offer potentially superior safety and efficacy profiles.

Lead program LAVA-051 targeting CD1d in multiple myeloma, CLL, and AML represents a clear collaboration or licensing entry point for regional or regional/global pharma companies looking to augment their immuno-oncology portfolios.

Clinical momentum Phase I/IIa readiness for LAVA-051 and the unique gamma-delta bsTCE platform can attract co-development deals, accelerated trial collaborations, or milestone-driven partnerships with biotech and pharma seeking innovative bispecific assets.

Financial angle Existing funding and a history of corporate activity including acquisition interest suggest opportunities for investment, licensing, or strategic partnerships to scale development and manufacturing capabilities.

Strategic outreach Engagement with potential acquirers or licensees in the gamma-delta space, including entities focused on Seagen-type EGFR targets or solid tumor programs, could unlock licensing of preclinical assets or exclusive rights to LAVA’s Gammabody technology.